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Abstract
Background: Lipoprotein Lipase (LPL), a key enzyme in lipid metabolism, catalyzes the hydrolysis
of triglycerides (TG) from TG-rich lipoproteins, and serves a bridging function that enhances the
cellular uptake of lipoproteins. Abnormalities in LPL function are associated with pathophysiological
conditions, including familial combined hyperlipidemia (FCH). Whereas two LPL susceptibility
alleles were found to co-segregate in a few FCH kindred, a role for common, protective alleles
remains unexplored. The LPL Ser447Stop (S447X) allele is associated with anti-atherogenic lipid
profiles and a modest reduction in risk for coronary disease. We hypothesize that significant
depletion of the 447X allele exists in combined hyperlipidemia cases versus controls. A case-
control design was employed. The polymorphism was assessed by restriction assay in 212 cases
and 161 controls. Genotypic, allelic, and phenotypic associations were examined.
Results: We found evidence of significant allelic (447Xcontrol: 0.130 vs. 447Xcase: 0.031, χ2 = 29.085;
1df; p < 0.001) and genotypic association (SS: 0.745 vs. 0.939, and SX+XX: 0.255 vs. 0.061) in
controls and cases, respectively (χ2 = 26.09; 1df; p < 0.001). In cases, depletion of the 447X allele
is associated with a significant elevation in very-low-density lipoprotein cholesterol (VLDL-C, p =
0.045). Consonant with previous studies of this polymorphism, regression models predict that
carriers of the 447X allele displayed significantly lower TG, low-density lipoprotein cholesterol
(LDL-C) and TG/high-density lipoprotein cholesterol (HDL-C) ratio.
Conclusion:  These findings suggest a role for the S447X polymorphism in combined
hyperlipidemia and demonstrate the importance of evaluating both susceptibility and protective
genetic risk factors.
Background
Abnormalities of lipoprotein metabolism play an impor-
tant role in the development of atherosclerosis [1,2], and
was one of the earliest established biochemical links to
cardiovascular disease [3]. It is well established that ele-
vated plasma triglycerides (TG) are an independent risk
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factor for coronary heart disease (CHD), and not simply a
marker of an inverse relationship with high density lipo-
protein-cholesterol (HDL-C), also an independent risk
factor for disease [4]. The relative risk of CHD associated
with a 1-mmol/L increase in TG was 1.32 (95% CI: 1.26–
1.39) in men and 1.76 (95% CI: 1.5–2.07) in women [4].
Thus, identifying factors that determine plasma TG is
desirable.
The contribution of lipoprotein lipase (LPL) in the devel-
opment of dyslipidemia and atherosclerosis is increas-
ingly recognized [5-7]. Numerous studies have shown
that LPL is a key enzyme that plays a central role in lipo-
protein metabolism and transport [8] and substantial evi-
dence suggests that LPL has an important influence on TG
levels [9]. In addition, LPL possesses a non-enzymatic
bridging function, assisting in cellular lipoprotein uptake
[10]. The finding of triglyceride-rich lipoproteins (TRL) in
human atheromata [11,12] has provided substantial
pathophysiologic evidence for a direct role of LPL in
atherogenesis. Importantly, hereditary forms of dyslipi-
demia have been in part attributed to ablative mutations
in LPL [13].
Though over 200 coding mutations within the LPL gene
(MIM 609708) have been described, the role for common
functional polymorphism of LPL, particularly in familial
combined hyperlipidemia (FCH [MIM 144250]), remains
poorly explored [14,15]. The most common amino acid
change in LPL is Ser447X (rs328; formally p.Ser474X,
c.1421C>G; but throughout the present report we have
kept to the traditional nomenclature for this polymor-
phism), resulting in an LPL protein truncated by two
amino acids [16]. It appears likely that the functional
properties of the 447X truncated LPL protein is an
enhanced bridging function, leading to increased clear-
ance of TRL from the circulation [5]. Interestingly, recent
cohort studies suggest that LPL 447X carriers appear to
have a more favorable lipid profile and this allele appears
to be a negative risk factor for coronary artery disease
(CAD) [17-19]. An interesting recent report of neonatal
somatic gene transfer with an adenoviral vector contain-
ing the S447X variant of LPL described rescue of 95% of
LPL-deficient mice from lethality [20]. This study is fur-
ther evidence of the gain of function of the S447X variant,
as pointed out by Rader [21], because considerably fewer
animals were rescued when the wild-type LPL vector had
been used previously [22].
FCH is the most prevalent genetic lipid disorder observed
in patients with CAD and their relatives, with a frequency
of 1–2% in all populations examined and a prevalence of
10%-20% in patients with premature CAD [23-27].
Hypertriglyceridemia is a major component of the pheno-
type of FCH, the most common of the dyslipidemias [25-
27]. The common metabolic defect in FCH appears to be
hepatic overproduction of apolipoprotein B-containing
TRL [28,29] and a preponderance of small dense low-den-
sity lipoprotein (LDL) particles [30,31]. Previously, we
and others have proposed a genetic model for FCH that
postulates the existence of both a common dominant
major gene(s) that is further influenced by a number of
modifier genes [23]. The identification of modifier genes
could assist in finding the as yet undiscovered primary
genetic determinant(s) by reducing the genetic heteroge-
neity of FCH [23].
Several reports have noted the presence of multiple lipo-
protein phenotypes in obligate heterozygotes for LPL
mutations that are reminiscent of FCH (i.e., hypertriglyc-
eridemia, hypercholesterolemia, or both) [32]. As much
as one-third of FCH patients have levels of post-heparin
LPL activity and mass below the 10th percentile for the
general population [32,33]. Given the multifactorial
nature of FCH, with other genetic or environmental fac-
tors (e.g., obesity) causing an increase in the hepatic pro-
duction of lipoproteins, the catabolic capacity of LPL in
individuals who are genetically predisposed to a low basal
level of LPL activity may be overwhelmed, exacerbating
the primary dyslipidemia and thus accelerating athero-
sclerosis [23]. Importantly, studies that have examined
the role of genetic variation of the LPL gene in FCH have
focused primarily on rare variations, mutations or intra-
genic markers [23,34-38].
The possibility that a disorder could be explained, at least
in part, by either enrichment of pro-atherogenic genetic
variations or depletion of anti-atherogenic ones led to our
interest in examining the later in combined hyperlipi-
demia. The occurrence of impaired LPL activity in individ-
uals with FCH suggested that examination of the anti-
atherogenic LPL 447X allele could introduce a novel par-
adigm in the study of this disease. The aim of this study
was to investigate the role of the LPL S447X polymor-
phism in a sample of subjects with combined hyperlipi-
demia and compare them with healthy controls. We
provide evidence of a genetic association with LPL S447X
with FCH and with lipoprotein composition in affected
individuals.
Results
Characteristics of the study groups
Based Baseline on the hypothesis that a functional varia-
tion at the LPL gene locus would differ in frequency
between dyslipidemic individuals and healthy controls,
we screened patients and control subjects for the S447X
polymorphism. The clinical characteristics of the two
groups are described in Table 1. Individuals with com-
bined hyperlipidemia displayed significantly elevated
VLDL-TG (t = -15.310, 286.34 df, p < 0.001), LDL-TG (ZLipids in Health and Disease 2006, 5:19 http://www.lipidworld.com/content/5/1/19
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= -13.656, p < 0.001) and HDL-TG (t = -9.524, 383.36 df,
p < 0.001) and decreased HDL-C (t = 10.010, 425.09 df, p
< 0.001) compared to controls.
BMI was significantly increased in cases compared to con-
trols (27.7 ± 4.54 vs. 25.3 ± 4.08; t = -4.170, p < 0.001
[95% CI: -3.53, -1.26]).
Frequencies of the SNPs
Allelic and genotypic frequencies for S447X in cases and
controls are listed in Table 2. The S447X genotype distri-
bution did not deviate from Hardy-Weinberg expectations
(χ2 = 1.585; 2df; p = 0.453). It is noteworthy that the
allelic and genotypic frequencies of the polymorphism in
the control group were similar to previous reports [39,40].
Compared to healthy controls, the 447X allele frequency
was significantly lower in cases (χ2 = 29.085; 1df; p <
0.001; Odds Ratio = 0.192 with 95%CI: 0.096–0.378)
(Table 2). Given the limited number of observations with
respect to homozygous 447X subjects (n = 1), the XX and
SX groups were collapsed for analysis. The genotypic dis-
tribution was significantly influenced by depletion of the
X allele in controls versus cases (χ2 = 26.087; 1df; p <
0.001; Odds Ratio = 0.191 with 95%CI: 0.098–0.371)
(Table 2A). Though no significant gender differences were
observed with respect to the S447X allelic or genotypic fre-
quencies (Table 2B), male cases versus controls displayed
a slightly greater depletion of the 447X allele (χ2 = 19.738;
1df; p < 0.001; Odds Ratio = 0.145 with 95%CI: 0.059–
0.355) than did female cases versus controls (χ2 = 6.388;
1df; p = 0.011; Odds Ratio = 0.267 with 95%CI: 0.099–
0.716). In the subset of subjects for whom BMI was
recorded along with baseline lipid assessments (n = 247),
no evidence of genetic association was observed in either
cases (n = 154, SS:SX+XX, p = 0.216) or controls (n = 93,
SS:SX+XX, p = 0.615).
Genetic association of lipid parameters with S447X
To examine the effects of the polymorphism on lipopro-
tein metabolism, fasting lipoprotein concentrations pro-
vided a metabolic 'snap shot' for comparisons between
carriers of the 447X allele and the 447S homozygotes. No
significant changes in mean measures of plasma lipopro-
tein compartments were observed in the control group
(Table 3). With the case group the S447 homozygotes dis-
played elevated VLDL-C (SS: SX+XX, Z = -2.003, p =
0.045) (Table 4). Suggestive evidence of an association
Table 1: Clinical characteristics and lipid analyses of the study population.
Trait Controls (n = 161) Cases (n = 212) p-value
Age 46.8 ± 19.57 (161) 53.2 ± 12.08 (211) <0.001
Gender(%female) 49.1 (161) 41.5 (212) < 0.09
TC 183.9 ± 36.66 (161) 293.9 ± 72.83 (212) *
TG 100.0 ± 37.81 (161) 376.7 ± 347.98 (212) *
VLDL-C 11.1 ± 7.77 (133) 69.0 ± 57.90 (212) *
VLDL-TG 47.7 ± 30.08 (133) 275.8 ± 256.25 (212) <0.001
LDL-C 122.1 ± 31.08 (133) 180.5 ± 55.96 (211) *
LDL-TG 29.9 ± 12.15 (133) 75.2 ± 177.92 (211) <0.001
HDL-C 52.9 ± 14.18 (158) 40.6 ± 12.48 (212) <0.001
HDL-TG 15.5 ± 4.88 (158) 21.7 ± 9.68 (212) <0.001
TG/HDL-C 1.97 ± 1.42 (158) 11.46 ± 17.59 (212) 0.211
BMI 25.3 ± 4.08 (93) 27.7 ± 4.54 (154) <0.001
With the exception of gender, means and standard deviations are reported. * Use of these variables as a case selection criterion precludes report 
of a statistic.
TC, total cholesterol; TG, triglyceride; VLDL-C, very low density lipoprotein – cholesterol; LDL-C, low density lipoprotein-cholesterol; HDL, high 
density lipoprotein; BMI, body mass index.
Table 2A: Allelic and genotypic frequencies.
Controls (n = 161) Cases (n = 212) p-value
447X 0.130 0.031 < 0.001
447 SS 0.745 0.939
447 SX 0.248 0.061
447 XX 0.006 0.000
447 (SX+XX) 0.255 0.0.061 < 0.001Lipids in Health and Disease 2006, 5:19 http://www.lipidworld.com/content/5/1/19
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with elevated VLDL-triglyceride (SS:SX+XX, Z = -1.883, p
= 0.06) and elevated HDL-TG (SS:SX+XX, Z = -1.778, p =
0.075) in carriers of the 447X allele was also observed
(Table 4).
Linear regression analysis of the effects of S447X on lipid 
measures
Regression models for lipid measurements included a
data-driven selection among the polymorphism category
SS versus SX+XX. Potential predictors included age, gen-
der, and clinical category (case or control). Models in
which a polymorphism effect did not achieve p < 0.10 are
not reported. Among the lipid measures, a logarithmic
transform was found to be generally appropriate for use in
the models. No significant models were indicated for TC,
VLDL-C, or VLDL-, LDL-, and HDL-triglyceride. For trans-
formed lipid measures, estimated adjusted means on the
original scale are presented (Table 5).
For total triglycerides (n = 372), the best model selected
SX+XX vs. SS (p = 0.001). Selected effects include gender
(p = 0.001), clinical category (p < 0.001) and genotype (p
= 0.062). The adjusted R-square for the model was 0.697
(Table 5). The group of S447 homozygotes displayed
modestly elevated plasma triglycerides compared with
carriers of the 447X allele (+19.7 mg/dL). For LDL-C (n =
345), the best model selected was also SX+XX vs. SS (p =
0.007). Selected effects included clinical category (p <
0.001) and genotype (p = 0.087). The adjusted R-square
for the model was 0.309 (Table 5). The group of S447
homozygotes displayed modestly elevated LDL-C as com-
pared with carriers of the 447X allele (+11.1 mg/dL). For
the ratio of total triglycerides to HDL-C (n = 370), the best
model selected was again SX+XX vs. SS (p = 0.031).
Selected effects include gender (p = 0.001), clinical cate-
gory (p < 0.001) and genotype (p = 0.044); the adjusted
R-square for the model was 0.651 (Table 5). The group of
S447 homozygotes displayed modestly elevated ratio as
compared with carriers of the 447X allele (+0.639).
Though BMI measurement was available on all subjects, a
measure of BMI at the same time point as the baseline
Table 2B: Allelic and genotypic frequencies, by gender.
Controls p-value Cases p-value
Female (n = 79) Male (n = 82) Female (n = 88) Male (n = 124)
447X 0.1139 0.1463 0.485 0.0034 0.0028 0.950
447 SS 0.784 0.707 0.343 0.932 0.944 0.952
447 (SX+XX) 0.215 0.293 0.068 0.056
447X, the minor allele for the lipoprotein lipase gene missense variation Serine447Stop (Ser447Ter, S447X); 447 SS, individuals homozygous for the 
Ser447 allele; 447 (SX+XX), individuals that carry either one or two 447X alleles.
Table 3: Plasma lipid concentrations in the control sample, grouped by LPL genotype.
SS (n = 120) SX + XX (n = 41) p-value
Age 45.4 ± 18.69 (120) 50.8 ± 21.67 (41) 0.131
BMI 25.5 ± 4.38 (68) 25.0 ± 3.19 (25) 0.615
TG* Total 92.1 ± 36.66 (120) 87.9 ± 41.30 (41) 0.544
VLDL 47.8 ± 30.01 (98) 47.3 ± 30.70 (35) 0.934
LDL 31.0 ± 12.30 (98) 27.0 ± 11.37 (35) 0.099
HDL 15.7 ± 4.83 (117) 14.8 ± 5.00 (41) 0.303
C* Total 184.8 ± 35.19 (120) 181.3 ± 41.01 (41) 0.654
VLDL 11.3 ± 8.17 (98) 10.6 ± 6.59 (35) 0.796
LDL 123.7 ± 27.00 (98) 117.5 ± 40.53 (35) 0.406
HDL 52.6 ± 15.33 (117) 53.9 ± 10.34 (41) 0.553
TG/HDL-C 2.05 ± 1.51 (117) 1.75 ± 1.08 (41) 0.211
*Lipid measurements expressed in mg/dL. Total cholesterol assessed by Wilcoxon two sample test.
TC, total cholesterol; TG, triglyceride; VLDL-C, very low density lipoprotein – cholesterol; LDL-C, low density lipoprotein-cholesterol; HDL, high 
density lipoprotein; BMI, body mass index; SS, individuals homozygous for the Ser447 allele; SX+XX, individuals that carry either one or two 447X 
alleles.Lipids in Health and Disease 2006, 5:19 http://www.lipidworld.com/content/5/1/19
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lipoprotein measurement was not available for all sub-
jects. Regression models including BMI resulted in unac-
ceptably small counts in cells, and thus analysis of the
subset including BMI was not reported.
Discussion
The common S447X truncation polymorphism of LPL is
associated with a cardio-protective lipid profile and a
modest reduction in risk for CAD [17]. Data from this
study support the hypothesis that there is significant
depletion in allelic and genotypic frequencies for this pro-
tective polymorphism in individuals with combined
hyperlipidemia compared to healthy controls. Specifi-
cally, we found that 447X exists in 13% of healthy con-
trols but only in 3% of cases (p < 0.001). The frequency of
447X in the control group is similar to that in the Fram-
ingham Offspring Study that examined 1114 men and
1144 women and found the frequency of the S447X vari-
ant was 16 and 17.5% in men and women, respectively
[19]. As in a previous report [19], data from this study
showed no significant gender differences with respect to
the LPL allelic or genotypic frequencies, though male
cases versus controls displayed a slightly greater depletion
of the 447X allele than did female cases versus controls.
Several population studies have reported cardio-protec-
tive alterations in lipoprotein profiles in subjects who
carry the 447X allele (e.g., lower TRL, lower VLDL-C,
higher apo AI levels, higher HDL-C, protection against
CHD) [5,7,41-44]. The linear regression analysis in this
study showed that carriers of the 447X allele displayed
modestly elevated plasma triglycerides (+19.7 mg/dL),
LDL-cholesterol (+11.1 mg/dL), and ratio of TG over
HDL-C (+0.639) as compared with carriers of the 447S
allele. These results are congruent with population studies
of cardiovascular disease that have reported similar effects
on TG [4,45], increased HDL-cholesterol, and 0.8-fold
reduced risk of ischemic heart disease in 447X carriers.
Although associations with favorable changes in both
VLDL-C [42] and HDL-C have been reported, no associa-
tion between LDL-C and this polymorphism has been
demonstrated previously. We believe that it is likely that
the case selection criterion we employed (elevated LDL-C)
could potentially account for the association between the
447X allele and lower LDL-C. Although another polymor-
Table 4: Plasma lipid concentrations in the combined hyperlipidemia subjects, grouped by LPL genotype.
SS (n = 199) SX + XX (n = 13) p-value
Age 53.3 ± 12.28 (198) 51.7 ± 8.70 (13) 0.647
BMI 27.6 ± 4.60 (145) 29.6 ± 3.21 (9) 0.216
TG* Total 383.8 ± 357.69 (199) 267.2 ± 65.24 (13) 0.099
VLDL 281.7 ± 262.98 (199) 184.6 ± 62.40 (13) 0.060
LDL 76.3 ± 183.55 (199) 59.4 ± 24.22 (13) 0.809
HDL 21.7 ± 8.72 (199) 21.9 ± 19.84 (13) 0.075
C* Total 295.5 ± 73.96 (199) 269.2 ± 48.10 (13) 0.264
VLDL 70.4 ± 59.29 (199) 48.4 ± 21.43 (13) 0.045
LDL 180.8 ± 56.74 (199) 175.3 ± 43.55 (13) 0.926
HDL 40.4 ± 11.87 (199) 43.7 ± 20.09 (13) 0.661
TG/HDLC 11.70 ± 18.07 (199) 7.82 ± 5.849 (13) 0.153
* Lipid measurements expressed in mg/dL. All test statistics are non-parametric (Wilcoxon two sample test).
TC, total cholesterol; TG, triglyceride; VLDL-C, very low density lipoprotein – cholesterol; LDL-C, low density lipoprotein-cholesterol; HDL, high 
density lipoprotein; BMI, body mass index; SS, individuals homozygous for the Ser447 allele; SX+XX, individuals that carry either one or two 447X 
alleles.
Table 5: Estimated adjusted means for plasma concentrations of plasma lipids, grouped according to LPL genotype.
Trait n SS* SX+XX* R2 p-value†
TG 373 165.8 146.1 0.697 0.001
LDL-C 345 144.5 133.4 0.309 0.007
TG/HDL-C 370 3.801 3.162 0.651 0.031
* Lipid measurements expressed in mg/dL. †The p-values are for the corresponding adjusted means on the log scale.
TG, triglyceride; LDL-C, low density lipoprotein-cholesterol; HDL, high density lipoprotein; SS, individuals homozygous for the Ser447 allele; 
SX+XX, individuals that carry either one or two 447X alleles.Lipids in Health and Disease 2006, 5:19 http://www.lipidworld.com/content/5/1/19
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phism within LPL has been associated with alterations in
the TG/HDL-C ratio [46], no study has previously
explored the impact of this polymorphism on the ratio.
However, one may infer that similar findings were dem-
onstrated in the longitudinal analysis of the Bogalusa
Heart Study (i.e., increased frequency of 447X in subjects
in the bottom quartile for plasma TG and HDL-C) [41].
Though several studies have examined the co-segregation
of genetic variations within the LPL gene region with the
occurrence of FCH [23], the few that have examined the
role of the 447X allele lacked sufficient power to evaluate
the significance of this polymorphism in FCH. Of the four
studies that examined the S447X polymorphism in 31
[47], 40 [36], 20 [37], and 30 [34] unrelated probands,
respectively, only Campagna and colleagues [34] reported
a modest effect of the S447X polymorphism on lipid lev-
els. Given the frequency of this polymorphism and the
sample sizes of these aforementioned studies, detection of
the genetic association reported here would not be
expected.
Potential study limitations include a possibility of selec-
tion bias of combined hyperlipidemia subjects without
the use of familial primary dyslipidemia criterion. A goal
of our group is to identify an endophenotype that would
allow the identification of individuals with FCH without
the resource intensive assessment of relatives. However, it
is important to note that our group has successfully vali-
dated several genetic associations reported for FCH
[48,49]. Another potential limitation involved the availa-
bility of BMI, an index known to impact lipoprotein
metabolism and lipid homeostasis [46,50], in the entire
study sample for inclusion in regression analyses.
Summary
As one would expect in a multifactorial model of a com-
mon disease, contributive alleles would be expected to
add an incremental risk of disease (i.e., CAD). Common
deficiencies in LPL may be the underlying causes of signif-
icant increases in CAD risk [1,2]. Understanding the role
that functional gene polymorphisms play in risk and
determining the levels of intermediate phenotypes (e.g.,
TG) is essential to our understanding of the important
metabolic pathways in the diseased and disease-free state.
Given the prevalence of the LPL S447X polymorphism in
the population, greater knowledge of the underlying con-
sequences of this variation may be of considerable impor-
tance in understanding genetic predisposition to
atherosclerosis and heart disease [51]. S447X is a com-
mon, functional variant and is associated with a beneficial
lipid profile, and is significantly depleted in patients with
combined hyperlipidemia. Importantly, understanding
the contribution not only of susceptibility alleles in dysli-
pidemia, but also of depletion of protective alleles, may
contribute materially to the identification of the genetic
determinants of heart disease.
Methods
Study design
This study was a retrospective analysis of the prevalence of
a common LPL polymorphism in non-Hispanic Cauca-
sian (European-descent) subjects with combined hyperli-
pidemia and a control group. Subjects were selected from
the University of California, San Francisco (UCSF)
Genomic Resource in Arteriosclerosis [52], using the fol-
lowing criteria: combined hyperlipidemia with total
plasma cholesterol (TC) > 200 mg/dL, total plasma TG >
200 mg/dL, LDL-C > 130 mg/dL, and very low density
lipoprotein-cholesterol (VLDL-C) > 30 mg/dL. Exclusion
criteria were: a diagnosis of familial hypercholestero-
lemia, hypothyroidism, or Type 2 Diabetes Mellitus.
Healthy non-Hispanic Caucasian (European-descent)
subjects with normal lipoprotein profiles comprised the
control group. All subjects gave informed consent in a
protocol approved by the UCSF Committee on Human
Research. With the exception of Body Mass Index (BMI, n
= 247) clinical and demographic data were available on
all subjects (n = 373).
Genotypic and phenotypic studies
Genomic DNA was prepared from whole blood and was
drawn after a 10-hour fast [52]. VLDL were prepared by
ultracentrifugation [53]. HDL-C was measured after pre-
cipitation of apo-B-containing lipoproteins with dextran
sulfate and magnesium [54]. Cholesterol and TG levels
were measured in plasma and in lipoprotein fractions by
either automated fluorescence method or automated
chemical analysis [55]. LDL-C was calculated as TC minus
HDL-C plus VLDL-C. Standards were provided by the
Centers for Disease Control (Atlanta, Georgia, USA). Base-
line lipoprotein measurements were obtained when
patients had received no lipid lowering medication for at
least 1 month. The presence or absence of the S447X pol-
ymorphism was determined as described previously [17].
Statistical methods
The SPSS for Windows (v11.0.1, 2001) system for statisti-
cal analysis was used. Allele and genotype frequencies
were determined by the gene-counting method. Tests for
Hardy-Weinberg equilibrium in controls, and allelic or
genotypic association in cases versus controls, were evalu-
ated by χ2 test. χ2 tests of allele frequency were adjusted
using Yates' Continuity Correction. Power transforma-
tions of potential predictor variables were examined
where appropriate. Two-group comparisons of means of
transformed or normally distributed variables used the
independent samples t-test. Two-group comparisons of
means of untransformed, non-normally distributed varia-
bles used the Wilcoxon two-sample test. The procedure,Lipids in Health and Disease 2006, 5:19 http://www.lipidworld.com/content/5/1/19
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general linear model (GLM), was used for linear regres-
sion models. Power transformations of potential predic-
tor variables were examined to maximize the explanatory
power of the overall model (by maximizing the F statis-
tic). Interactions between covariates and genotypes were
evaluated. Selected interaction effects and covariate-
adjusted means of the transformed responses for levels of
categorical factors were tested using procedure GLM.
Interaction effects with p < 0.10 were retained. For multi-
ple comparisons between factor levels, Bonferroni-cor-
rected p-values are reported.
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